Industry
Biotechnology
ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and IMMULINA, a Braun-type lipoproteins, including spirulina extracts and active compounds, which are used to support human immune function. It also offers analytical reference standards and services comprising supply of products to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, life sciences, and pharmaceutical industries. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation is headquartered in Los Angeles, California.
Loading...
Open
7.03
Mkt cap
521M
Volume
1M
High
7.13
P/E Ratio
341.00
52-wk high
7.58
Low
6.80
Div yield
N/A
52-wk low
1.32
Portfolio Pulse from Benzinga Newsdesk
November 01, 2024 | 11:07 am
Portfolio Pulse from Benzinga Insights
October 31, 2024 | 8:34 pm
Portfolio Pulse from Benzinga Newsdesk
October 31, 2024 | 8:23 pm
Portfolio Pulse from Benzinga Newsdesk
October 31, 2024 | 8:16 pm
Portfolio Pulse from Benzinga Newsdesk
October 31, 2024 | 8:06 pm
Portfolio Pulse from Benzinga Insights
October 30, 2024 | 9:04 pm
Portfolio Pulse from Benzinga Newsdesk
September 20, 2024 | 12:33 pm
Portfolio Pulse from Benzinga Newsdesk
September 10, 2024 | 12:35 pm
Portfolio Pulse from Benzinga Newsdesk
August 19, 2024 | 12:33 pm
Portfolio Pulse from Benzinga Newsdesk
August 09, 2024 | 9:30 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.